Derren Nathan

Derren Nathan

Head of Equity Research

Derren leads our Equity Research team with more than 15 years of experience in his field. Derren enjoys exploring the complex pharmaceutical sector and presenting share ideas for retail investors. He focuses on identifying exceptional companies poised for long-term success through outstanding customer propositions, translating into potential market-beating growth or sustainable dividends.

Covers

Share research and insight

Latest content from Derren

July 2025

British American Tobacco: full-year guidance firms as US starts to recover
31st July 2025
Anglo American: tough diamond market drags on first half performance
31st July 2025
Haleon: full-year revenue guidance cut, profit outlook remains healthy
31st July 2025
Shell: second quarter profit falls but buybacks continue
31st July 2025
Rio Tinto: lower prices and tariff impact push H1 profits lower
30th July 2025
Visa: Q3 results beat expectations
30th July 2025
Is there a nuclear energy renaissance? – plus 2 share ideas
30th July 2025
Baker Hughes: $13.6bn agreement to acquire Chart Industries
30th July 2025
GSK: heading for top end of guidance after robust Q2
30th July 2025
Croda: H1 sales and margins improve in challenging environment
29th July 2025
AstraZeneca: guidance unchanged after solid first half growth
29th July 2025
PayPal: solid Q2, guidance nudged higher
29th July 2025
Novo Nordisk: full-year guidance cut, new CEO announced
29th July 2025
Next week on the stock market
25th July 2025
Mitchells & Butlers: strong Q3 trading performance
25th July 2025
CVS Group: full year trading in-line, underlying sales growth stalls
24th July 2025
Baker Hughes: second-quarter revenue dips, but margins improve
23rd July 2025
JD Wetherspoon: growing steadily in final quarter
23rd July 2025
FTSE 100 hits 9000 and new record high – 3 stocks to watch
22nd July 2025
SSE: weather dents Q1 renewables output
17th July 2025
easyJet: strong Q3, but French strikers weigh on outlook
17th July 2025
Diageo: CEO steps down with immediate effect
17th July 2025
Rio Tinto: Iron Ore boss Trott to become CEO
15th July 2025
Next week on the stock market
4th July 2025
US stock market reaches new record high – 3 S&P 500 share ideas
2nd July 2025

May 2025

Next week on the stock market
30th May 2025
Investing in weight-loss drug stocks – who are the frontrunners?
30th May 2025
NVIDIA: first quarter demonstrates strong underlying demand
29th May 2025
Pets at Home: full-year profit as expected but guidance lower this year
28th May 2025
Mitchells & Butlers: strong first half, market remains robust
22nd May 2025
Rio Tinto: Jakob Stausholm CEO to step down later this year
22nd May 2025
British Land: robust results but near-term outlook disappoints
22nd May 2025
Tate & Lyle: full year results meet expectations, soft outlook
22nd May 2025
Greggs: sales growth picks up after a slow start to the year
20th May 2025
Primary Health Properties: raises bid to £1.68bn to acquire Assura
19th May 2025
Novo Nordisk: CEO to step down due to market challenges
19th May 2025
Aviva: robust Q1, Direct Line deal expected to close mid-year
15th May 2025
Alibaba: Q4 profits grow, but cash flow comes under pressure
15th May 2025
Compass Group: full year guidance unchanged after strong first half
14th May 2025
Imperial Brands: full year guidance intact, more to do in H2
14th May 2025
Experian: More growth expected after topping margin guidance
14th May 2025
3 share ideas that could benefit from a truce in the trade war
13th May 2025
Next week on the stock market
9th May 2025
Novo Nordisk: Strong first quarter but full-year guidance lowered
7th May 2025
J D Wetherspoon: Q3 sales rise
7th May 2025
AMD: beats Q1 forecasts, China weighs on outlook
7th May 2025
Shell: Q1 profit beat and $3.5bn buyback
2nd May 2025
Chevron: caution on buybacks after Q1 profit falls
2nd May 2025
Haleon: capital markets day update
2nd May 2025
Next week on the stock market
2nd May 2025
Mastercard: strong Q1 with full year guidance intact
1st May 2025
Whitbread: annual profit dips on soft demand for UK hotels
1st May 2025
Eli Lilly: sales targets intact after Q1 growth of 45%
1st May 2025
CVS Group: sentiment rallies on initial CMA proposals
1st May 2025

April 2025

Visa: small Q2 beat, buyback program refreshed
30th April 2025
Haleon: encouraging Q1, outlook unchanged
30th April 2025
Smith & Nephew: guidance unchanged after first quarter
30th April 2025
GSK: guidance unchanged after small first quarter sales beat
30th April 2025
BP: guidance broadly unchanged after first quarter
29th April 2025
AstraZeneca: double digit sales and profit growth in first quarter
29th April 2025
Paypal: full year guidance maintained despite macro uncertainty
29th April 2025
Next week on the stock market
25th April 2025
Five shares to watch in 2025 – how have they started the year?
24th April 2025
Baker Hughes: resilient Q1 but tariffs temper outlook
23rd April 2025
Croda: full-year guidance unchanged as volumes drive Q1 sales growth
23rd April 2025
Next week on the stock market
16th April 2025
Next week on the stock market
11th April 2025
Big oil stocks, Trump’s tariffs and the energy transition – what’s next for investors?
4th April 2025

Social handles

@nathan_derren

CV

Head of Equity Research

Hargreaves Lansdown

July 2022 - Present

Head of Research

Hybridian LLP

July 2018 - July 2022 • 4 yrs 1 mo

Investment research

Hybridian LLP

Apr 2014 - July 2022 • 8 yrs 4 mos

In the press

Press articles quoting or featuring our experts and spokespeople. Hargreaves Lansdown is not responsible for these articles’ content and accuracy and may not share the views of the author or publication listed below.

dailymail.co.uk
Chancellor Jeremy Hunt's plan to sell off NatWest shares 'could cost taxpayers £28bn'
morningstar.com
Traders boost bets on mid-2024 rate cut by Bank of England as U.K. jobs market cools
thisismoney.co.uk
Analysts eye more M&A for Britain's hospitality sector